The suppression of the SPHK1/S1P/S1PR3 signaling pathway diminishes EGFR activation and increases the sensitivity of non-small cell lung cancer to gefitinib

Non-small-cell lung cancer (NSCLC) represents a predominant histological subtype of lung cancer, characterized by high incidence and mortality rates. Despite significant advancements in therapeutic strategies and a deeper understanding of targeted therapies in recent years, tumor resistance remains...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Jing Zhang, Zequn Wang, Xihua Wei, Mengyuan Han, Ribai Yan, Lijie Ma, Yan Pan
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2025-01-01
Saila:	Current Research in Pharmacology and Drug Discovery
Gaiak:	Sphingosine kinase 1 Sphingosine-1-phosphate Sphingosine 1-phosphate receptor Gefitinib Non-small-cell lung cancer
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2590257124000397
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!